Skip to main content

JAK/TYK2

Dr. John Cush
@RheumNow
New FDA Approved for Polymyalgia Rheumatica - Secukinumab The US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate a https://t.co/kmgEiZIiFS
Jiha Lee
@JihaRheum
A#2929 JAKi vs TNFi in RA (TriNetX, N>32k): mortality HR 1.28 at 3yr, yet MACE null until 5yr (HR 1.06). Mortality ahead of MACE may reflect non-CV deaths? Channeling, confounding by indication and switchers may bias the comparison @rheumnow #ACR26
Audrey Gibson
@Gibson_RheumPAC
Zeng et al: TARA phase 3 in bDMARD-refractory RA: Week 24 ACR50 was 73.0% with girocitinib vs 49.5% with tofacitinib (p<0.0001). Impressive efficacy; longer-term safety remains critical. @rheumnow #ACR2026 Abstract#LB21
sheila
@RHEUMarampa
TARA trial: Ph3 H2H trial of Girocitinib (JAK1/TYK2i) vs Tofa in RA refractory to bDMARDs Giro achieved higher ACR50 response vs Tofa at wk24 (73 vs 49.5%) Also met secondary endpts Safety data: Infections more common. No VT/malignancy/MACE in Giro arm. @RheumNow #ACR26 LB21 https://t.co/HNVt7WdLc6

Is It Still Inflammation?

Antoni Chan, MD, PhD

A 34 year old female has axSpA. Her CRP is 3, her MRI is quiet, and her BASDAI is 7. She has tried two biologics and is asking about a third. Before we write that prescription, #ACR26 challenges us to ask a different question: is it still inflammation?

Mrinalini Dey
@DrMiniDey
Could blood proteins guide JAKi vs TNFi selection? A 7-protein model discriminated opposite 6-month remission outcomes in advanced-therapy-naive RA (AUC 0.75), but performed poorly after prior therapy (0.57). @Rheumnow #2829 #ACR26
×